Makena Compounding Case Dismissed - FDA's Enforcement Discretion Not Subject to Judicial Review - FDA Lawyers Blog:
"Regarding K-V's assertion that FDA would exercise broad enforcement discretion for compounded versions of Makena™, FDA stated:
In order to support access to this important drug, at this time and under this unique situation, FDA does not intent to take enforcement action against pharmacies that compound hydroxyprogesterone caproate based on a valid prescription for an individually identified patient unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products. As always, FDA may at any time revisit a decision to exercise enforcement discretion."
'via Blog this'
Return Home: The Designated Representative and Exemptee Blog
CA Designated Representative online CBT training certification by SkillsPlus Intl Inc.
FL Designated Representative online CBT exam preparation by SkillsPlus Intl Inc.
CA HMDR Exemptee online CBT training certification by SkillsPlus Intl Inc.
SkillsPlus Intl Info Blog